|
Acquisitions - Additional Information (Detail) (USD $)
Share data in Millions, unless otherwise specified |
0 Months Ended | 12 Months Ended |
|---|---|---|
|
Jan. 17, 2012
|
Dec. 31, 2013
|
|
|
OncoHist [Member]
|
||
| Business Acquisition [Line Items] | ||
| Fair value of intangible asset | $ 10,559,820 | |
|
SymbioTec GmbH [Member]
|
||
| Business Acquisition [Line Items] | ||
| Shares of common stock exchanged in acquisition | 25.6 | |
| Business acquisitions full consideration transferred | 9,750,000 | |
| Business acquisition, Assumption of note payable | 411,000 | |
| Business acquisition, Stock issuance costs | 80774 | |
| Business acquisition, Description | SymbioTec is principally focused on the discovery of therapies designed to treat cancer in humans. SymbioTec's lead product candidate, OncoHist, is in the pre-clinical stage of development for the treatment of refractory AML and Non-Hodgkins Lymphoma. OncoHist has been granted orphan drug status by both the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency. | |
| Forecasting period for revenue and operating projections | 18 years | |
| Discount rate used to estimate fair value of intangible asset | 50.00% | |
| Estimated cost to complete pre-clinical work for IND filing | 10,000,000 | |
|
SymbioTec GmbH [Member] | OncoHist [Member]
|
||
| Business Acquisition [Line Items] | ||
| Fair value of intangible asset | $ 9,580,000 |
| X | ||||||||||
|
- Definition
With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents disclosure of the line item or line items in the financial statements in which the amount of any issuance related costs which have not been expensed are recognized including, as appropriate, the accounting treatment applied. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Discount rate used to estimate the fair value of servicing assets and servicing liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Business Combination Purchase Consideration Notes Payable No definition available.
|
| X | ||||||||||
|
- Definition
Estimated Cost To Complete Pre-Clinical Work For Investigation New Drug Filing No definition available.
|
| X | ||||||||||
|
- Definition
Exchange Of Common Stock Shares Shares No definition available.
|
| X | ||||||||||
|
- Definition
Forecasting Period No definition available.
|